Re-engineering the immune system
Utilizing the small, but mighty, alpaca-derived nanobodies as versatile drug targeting agents
Initial programs focus on developing therapies for autoimmune and infectious diseases
Cerberus Therapeutics is committed to revolutionizing healthcare through our pioneering nanobody technology. With a focus on autoimmunity and infectious diseases, we aspire to reshape the future of medicine and improve the lives of countless individuals.
Cerberus Therapeutics is established by Dr. Novalia Pishesha, Professor Hidde Ploegh, and Professor Harvey Lodish, Ph.D. Our innovative approach harnesses the power of nanobodies derived from alpacas, unlocking new possibilities in the fields of autoimmunity and infectious diseases.
At Cerberus, we have developed two distinct nanobody-based platforms. The first platform is dedicated to combating autoimmunity by targeting major histocompatibility complex class II antigens (MHC II), engaging various professional antigen-presenting cells such as dendritic cells, macrophages, and B cells. This approach "instructs" and "empowers" the immune system to rewire itself, potentially presenting a cure for immune-mediated diseases.
Cerberus' infectious disease platform employs engineered nanobodies that recognize antibody light chains. These nanobodies are combined with small molecule antivirals or pathogen-specific nanobodies to create powerful adducts. These adducts are strategically designed to activate the complement system and engage polyclonal antibodies, mounting a robust protective response against the recognized pathogen with vaccines effects.
As a growing biotech startup, we are always looking for new team members. Whether you’re interested in the science, business development, or have something unique to bring to the team, we’d love to chat with you! We value team players who are driven by challenges and curiosity. Reach out to us and send your CV to firstname.lastname@example.org
Establishing and executing protocols in immunology, performing ex vivo, and in vivo assays with the goal of investigating the efficacy of Cerberus’ novel therapeutic leads as treatment for autoimmune diseases.